TD Cowen Reiterates Buy Rating on C4 Therapeutics (CCCC) Feb 26, 2026 10:56AM
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Feb 26, 2026 07:00AM
C4 Therapeutics to Participate in Upcoming March Conferences Feb 23, 2026 07:10AM
TD Cowen Starts C4 Therapeutics (CCCC) at Buy Dec 2, 2025 05:36AM
C4 Therapeutics prices $125 million stock offering Oct 16, 2025 07:08AM


Oct 16, 2025 07:08AM C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
Feb 27, 2025 07:00AM C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Feb 24, 2025 07:00AM C4 Therapeutics to Participate in Upcoming March Investor Conferences
Feb 22, 2024 07:00AM C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Feb 23, 2023 07:00AM C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
Feb 23, 2023 07:00AM C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
Feb 24, 2022 07:00AM C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
Feb 24, 2022 07:00AM C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
Jan 10, 2022 07:03AM C4 Therapeutics Inc. (CCCC) Announces Key 2022 Milestones and Priorities
Jan 10, 2022 07:00AM C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio
Jan 10, 2022 07:00AM C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio
Feb 24, 2021 07:00AM C4 Therapeutics to Participate in Upcoming March Investor Conferences
Feb 24, 2021 07:00AM C4 Therapeutics to Participate in Upcoming March Investor Conferences